KRAS is mutated in approximately 90% of pancreatic ductal adenocarcinoma (PDAC) including 35% KRASG12D, 30% KRASG12V, 15% KRASG12R, and 1-2% KRASG12C [1, 2]. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.